These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 11896112

  • 1. Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study.
    Furman WL, Stewart CF, Kirstein M, Kepner JL, Bernstein ML, Kung F, Vietti TJ, Steuber CP, Becton DL, Baruchel S, Pratt C.
    J Clin Oncol; 2002 Mar 15; 20(6):1617-24. PubMed ID: 11896112
    [Abstract] [Full Text] [Related]

  • 2. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ, Burris H, Schellens JH, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Fields S, Von Hoff DD, Verweij J.
    Clin Cancer Res; 1998 May 15; 4(5):1153-8. PubMed ID: 9607572
    [Abstract] [Full Text] [Related]

  • 3. A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.
    Rowinsky EK, Kaufmann SH, Baker SD, Miller CB, Sartorius SE, Bowling MK, Chen TL, Donehower RC, Gore SD.
    Clin Cancer Res; 1996 Dec 15; 2(12):1921-30. PubMed ID: 9816150
    [Abstract] [Full Text] [Related]

  • 4. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
    Steinherz PG, Shukla N, Kobos R, Steinherz L.
    Pediatr Blood Cancer; 2010 May 15; 54(5):687-93. PubMed ID: 20205253
    [Abstract] [Full Text] [Related]

  • 5. Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan.
    Akhtar S, Beckman RA, Mould DR, Doyle E, Fields SZ, Wright J.
    Cancer Chemother Pharmacol; 2000 May 15; 46(3):204-10. PubMed ID: 11021737
    [Abstract] [Full Text] [Related]

  • 6. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
    Rowinsky EK, Grochow LB, Sartorius SE, Bowling MK, Kaufmann SH, Peereboom D, Donehower RC.
    J Clin Oncol; 1996 Apr 15; 14(4):1224-35. PubMed ID: 8648378
    [Abstract] [Full Text] [Related]

  • 7. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
    Rowinsky EK, Adjei A, Donehower RC, Gore SD, Jones RJ, Burke PJ, Cheng YC, Grochow LB, Kaufmann SH.
    J Clin Oncol; 1994 Oct 15; 12(10):2193-203. PubMed ID: 7931489
    [Abstract] [Full Text] [Related]

  • 8. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors.
    Daw NC, Santana VM, Iacono LC, Furman WL, Hawkins DR, Houghton PJ, Panetta JC, Gajjar AJ, Stewart CF.
    J Clin Oncol; 2004 Mar 01; 22(5):829-37. PubMed ID: 14990638
    [Abstract] [Full Text] [Related]

  • 9. A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.
    Cooper BW, Veal GJ, Radivoyevitch T, Tilby MJ, Meyerson HJ, Lazarus HM, Koc ON, Creger RJ, Pearson G, Nowell GM, Gosky D, Ingalls ST, Hoppel CL, Gerson SL.
    Clin Cancer Res; 2004 Oct 15; 10(20):6830-9. PubMed ID: 15501959
    [Abstract] [Full Text] [Related]

  • 10. Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors.
    Rodriguez-Galindo C, Crews KR, Stewart CF, Furman W, Panetta JC, Daw NC, Cain A, Tan M, Houghton PH, Santana VM.
    Cancer Chemother Pharmacol; 2006 Jan 15; 57(1):15-24. PubMed ID: 16001174
    [Abstract] [Full Text] [Related]

  • 11. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
    Giles FJ, Faderl S, Thomas DA, Cortes JE, Garcia-Manero G, Douer D, Levine AM, Koller CA, Jeha SS, O'Brien SM, Estey EH, Kantarjian HM.
    J Clin Oncol; 2003 Mar 15; 21(6):1050-6. PubMed ID: 12637470
    [Abstract] [Full Text] [Related]

  • 12. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study.
    Tubergen DG, Stewart CF, Pratt CB, Zamboni WC, Winick N, Santana VM, Dryer ZA, Kurtzberg J, Bell B, Grier H, Vietti TJ.
    J Pediatr Hematol Oncol; 1996 Nov 15; 18(4):352-61. PubMed ID: 8888741
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.
    Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ.
    J Clin Oncol; 1994 Mar 15; 12(3):553-9. PubMed ID: 8120553
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Topotecan in the treatment of refractory neuroblastoma and other malignant tumors in childhood - a phase-II-study.
    Längler A, Christaras A, Abshagen K, Krauth K, Hero B, Berthold F.
    Klin Padiatr; 2002 Mar 15; 214(4):153-6. PubMed ID: 12165894
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group.
    Frangoul H, Ames MM, Mosher RB, Reid JM, Krailo MD, Seibel NL, Shaw DW, Steinherz PG, Whitlock JA, Holcenberg JS.
    Clin Cancer Res; 1999 Dec 15; 5(12):3956-62. PubMed ID: 10632325
    [Abstract] [Full Text] [Related]

  • 19. Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia.
    Seiter K, Feldman EJ, Halicka HD, Traganos F, Darzynkiewicz Z, Lake D, Ahmed T.
    J Clin Oncol; 1997 Jan 15; 15(1):44-51. PubMed ID: 8996123
    [Abstract] [Full Text] [Related]

  • 20. Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia.
    Inaba H, Stewart CF, Crews KR, Yang S, Pounds S, Pui CH, Rubnitz JE, Razzouk BI, Ribeiro RC.
    Cancer; 2010 Jan 01; 116(1):98-105. PubMed ID: 19885837
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.